The city of Seattle, Washington, currently has 85 active clinical trials seeking participants for Lymphoma research studies.
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Recruiting
To evaluate the tolerability,feasibility, and efficacy of combining acalabrutinib with RICE chemotherapy as second line therapy in relapsed/refractory DLBCL patients with separate primary objectives in each of in two cohorts: Cohort A: Hematopoeitic stem cell transplantation (HSCT) eligible patients undergoing second-line salvage chemoimmunotherapy [Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE)] plus acalabrutinib:. Cohort B: Individuals not eligible for HSCT undergoing second-line... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
07/20/2022
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Diffuse Large B Cell Lymphoma